Dynamic Contrast Ultrasound Diagnostics (CEUS) of Liver Lesions and Post-treatment Control with A New High-resolution Examination Technique (HiFR) and Perfusion

Ernst Michael Jung(University Hospital Regensburg), F. Jung(Brandenburg University of Technology Cottbus-Senftenberg), Yi Dong(Yunnan University), Christian Stroszczynski(University Hospital Carl Gustav Carus), Ulrich Kaiser(University of Applied Sciences Landshut), Lukas Pleyer(University Hospital Regensburg), Ivor Dropco(University Hospital Regensburg)
Journal of Gastrointestinal and Liver Diseases
September 29, 2024
10.15403/jgld-5589
Cited by 3

Related Papers

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
|The Lancet|2013|1.5k
Vascular Endothelial Cell Biology: An Update
|International Journal of Molecular Sciences|2019|1.1k
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial
|The Lancet Oncology|2009|960
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
|The Lancet Oncology|2015|402
Incidence and risk factors of central nervous system recurrence in aggressive lymphoma—a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)
|Annals of Oncology|2006|280